FERRIC CARBOXYMALTOSE FOR IRON-DEFICIENCY ANAEMIA

A Breakthrough Solution for Effective and Convenient Treatment

New dosage variant, containing ferric carboxymaltose (FCM), aims to provide a more effective and convenient treatment option for patients suffering from iron deficiency and iron deficiency anaemia (IDA).

Iron deficiency anaemia poses a significant burden, particularly for women during the later stages of pregnancy and as a result of postpartum haemorrhage (PPH). Indian studies reveal that approximately 36% of maternal deaths are attributed to PPH. Moreover, urban and rural areas report anaemia during pregnancy among 45.7% and 54.3% of pregnant women respectively, which hampers maternal and early child health outcomes in the postpartum period Emcure Pharmaceuticals Limited has proudly announced the launch of Orofer FCM 750, a groundbreaking addition to its parenteral iron brand This new dosage variant, containing ferric carboxymaltose (FCM), aims to provide a more effective and convenient treatment option for patients suffering from iron deficiency and iron deficiency anaemia (IDA). With approval from the Drug Controller General of India (DCGI), FCM is indicated for cases where oral iron preparations prove ineffective or cannot be utilized Currently available in 1000mg/20ml and 500mg/10ml singleuse vials, Orofer FCM will now also be offered as a 750mg/15ml dosage form, specifically recommended for patients with haemoglobin levels below 10 g/dl and body weights ranging from 35-70kg. It is important to note that Orofer FCM can only be obtained through a prescription from a registered medical practitioner.

Studies conducted in India involving FCM for the treatment of IDA in pregnancy have shown that most patients have a mean haemoglobin level below 10 g/dl. These patients may require FCM doses of up to 1500mg for body weights ranging from 35-70kg. Notably, a single dose of FCM containing up to 750mg of iron can be administered within a short time frame of 15 minutes, diluted in 250ml of normal saline

Commenting on the launch, Anil Kothiyal, President of India Business at Emcure Pharmaceuticals, expressed their commitment to addressing IDA as a significant public health concern in India, particularly among women Kothiyal stated, "We are proud to introduce Orofer FCM 750, which will help alleviate the substantial burden of IDA in our country. We believe that Orofer FCM 750, with its convenient dosage strength, will provide a crucial treatment option for patients with IDA who may not have responded to oral iron preparations or who are unable to tolerate them " Kothiyal further added that Orofer FCM 750 will soon be available in leading pharmacies and hospitals across the country.

The introduction of Orofer FCM 750 marks a significant milestone in addressing the complex issue of iron deficiency anaemia in India. By offering an alternative treatment option for patients who have not experienced success with oral iron preparations or face challenges in tolerating them, Emcure Pharmaceuticals is demonstrating its commitment to improving the lives of individuals affected by this condition. The convenient dosage strength of Orofer FCM 750 provides a streamlined approach to treatment, ensuring that patients receive the necessary iron supplementation efficiently and effectively

As Emcure Pharmaceuticals takes this crucial step forward, it underlines the company's dedication to advancing healthcare in India The launch of Orofer FCM 750 reinforces their mission to provide innovative and accessible solutions that enhance patient well-being. In conclusion, the introduction of Orofer FCM 750 offers hope to countless individuals grappling with iron